e are on the verge of a lifespan revolution. Life expectancy is going to rise to between 110 and 130 in the next 30 years. This is not science fiction.”
Jim Mellon’s vision may be optimistic but it’s certainly not fanciful. He came to the conclusions he draws in his new book, Juvenescence, after he immersed himself in the subject of longevity research for well over a year.
This included a 7,000-mile road trip around America, visiting scientists at the cutting edge of this research.
He’s not doing it for the money: Mellon’s wealth is estimated at £920m and he’s giving away the profits from the book to help fund further research into anti-ageing.
Neither is he a starry-eyed optimist. His first book, Wake Up! Survive and Prosper in the Coming Economic Turmoil warned – correctly of course – of the impending financial crisis. Since then his predictions have been followed closely by investors.
He has already written about disruptive technology and investing in drug research, and this new
Visionary investor Jim Mellon thinks so. Julie Blackburn reviews his new book